SAN

Sanofi stands at an inflection point that most large-cap pharmaceutical companies never reach: the moment when a single franchise rewrites the entire company's strategic identity. Dupixent, the interleukin-4 and interleukin-13 inhibitor that has become the best-selling drug launch in pharmaceutical history outside of oncology, is no longer just a product. It is a structural platform that defines how competitors position themselves in immunology, how payers negotiate biologics pricing, and how physicians treat a growing spectrum of Type 2 inflammatory diseases. The drug generated the majority of Sanofi's specialty care growth in recent years, and its indication expansion into chronic obstructive pulmonary disease (COPD) and food allergy has extended its commercial runway well into the 2030s.

Yet the market prices Sanofi at approximately EUR 79 per share against a market capitalization of roughly EUR 96 billion, a valuation that reflects deep skepticism. The price-to-earnings ratio of approximately 12.9 on FY2025 earnings, combined with a DCF estimate suggesting intrinsic value near EUR 191, reveals a company whose structural transformation is materially underappreciated. Sanofi's FY2025 revenue of EUR 43.6 billion, net income of EUR 7.8 billion, and free cash flow of nearly EUR 9 billion paint a picture of a company generating significant cash while simultaneously increasing its R&D investment by 37% over four years. The central analytical question is not whether Sanofi is a good pharmaceutical company. It is whether the market recognizes that Sanofi has transitioned from a diversified healthcare conglomerate into a focused biologics and vaccines powerhouse, and what structural position that transformation confers.

The L17X insight on Sanofi is this: the company's moat does not reside in any single drug's patent life, but in the compounding effect of indication expansion across a single biologic platform. Every new Dupixent approval does not merely add incremental revenue; it deepens prescriber familiarity, broadens payer formulary entrenchment, and raises the clinical evidence threshold that any competitor must clear. This is a pharmaceutical moat that grows wider with time, not narrower. It is the inverse of typical patent cliff dynamics, and the market has not priced it correctly.